Exact Sciences shares are trading higher after the company shared new modeling data on the projected impact of its Cologuard test since its FDA approval.
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences shares are trading higher after the company shared new modeling data on the projected impact of its Cologuard test since its FDA approval.
August 15, 2024 | 7:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences shares are trading higher after the company shared new modeling data on the projected impact of its Cologuard test since its FDA approval.
The release of positive modeling data on the Cologuard test, which has been FDA approved, is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100